Pfizer Scientist Will Kick Off Bioinformatics Lecture Series Nov. 4
For release: October 25, 2004
For press information, contact Gabrielle Maxey

The inaugural Pfizer Lecture in Bioinformatics at the University of Memphis will be presented by Dr. Jim Cavalcoli on Thursday, Nov. 4, at the FedEx Institute of Technology on the U of M campus. A reception will begin at 4 p.m. in the lobby, followed by the lecture at 5 p.m. in the Zone. The lecture, "Bioinformatics: Today and Tomorrow," is free and open to the public.

Cavalcoli is assistant director of the bioinformatics group at Pfizer Global Research and Development in Ann Arbor, Mich. His research efforts include support of five major therapeutic areas for drug discovery. He and his team develop algorithms and novel techniques for discovering drugs, and they work with scientists to analyze data and implement bioinformatics solutions. Their areas of focus include gene expression databases, new target discovery, and annotation and informatics relating to genomic and proteomic efforts.

Cavalcoli earned a doctorate in virology and molecular biology from Louisiana State University. Following three years of post-doctoral work at the University of Pittsburgh, he joined Pfizer (then Parke-Davis), where he has been for seven years.

Pfizer Inc. recently donated $15,000 to the University of Memphis to establish the lectureship program. Under a three-year agreement, the Pfizer Lectureship in Bioinformatics will bring a leading research investigator or business leader to campus annually.

The University of Memphis is a comprehensive metropolitan university offering 15 bachelor's degrees in more than 50 majors and 70 concentrations, master's degrees in 46 subjects, and doctoral degrees in 21 disciplines, in addition to the juris doctor (law) degree and a specialist degree in education.

Pfizer Inc., headquartered in New York City, discovers, develops, manufactures, and markets leading prescription medicines for humans and animals and many of the world's best-known consumer brands.

More News Releases